The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Comprehensive genomic characterization of CTCs in multiple myeloma
In this interview, Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, discusses the genomic characterization of circulating tumor cells (CTCs) in multiple myeloma (MM). A novel whole-genome sequencing (WGS)-based clinical assay has been developed that can enable comprehensive profiling of the myeloma cancer genome and allow for early detection of genetic alterations that confer resistance to therapy. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Maybe the time is now for CTC assessment in myeloma, the assessment of circulating tumor cells. We have the methodology, particularly next-generation flow cytometry, to detect with very high sensitivity in a standardized way. This is a breakthrough that is possible in recent years. Now the detection and quantification is already important and prognostic and may be clinically relevant in all stages of disease – MGUS, smoldering myeloma, newly diagnosed active myeloma, and even during treatment, the assessment of peripheral residual disease based on CTCs...
Maybe the time is now for CTC assessment in myeloma, the assessment of circulating tumor cells. We have the methodology, particularly next-generation flow cytometry, to detect with very high sensitivity in a standardized way. This is a breakthrough that is possible in recent years. Now the detection and quantification is already important and prognostic and may be clinically relevant in all stages of disease – MGUS, smoldering myeloma, newly diagnosed active myeloma, and even during treatment, the assessment of peripheral residual disease based on CTCs. This is already extraordinary. Now, what if, beyond or in addition to detection and quantification, we could characterize the CTC clone from the genomic point of view. And this is where this abstract is providing the means, the tools that allow for genomic characterization of only a few CTCs with very robust methodology. So I think this will be a breakthrough in the field. Finally, not only detection, quantification, but also now genomic characterization of this clinically relevant subclone in the myeloma space.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
